miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer by Chiyomaru, T et al.
miR-145 and miR-133a function as tumour suppressors and
directly regulate FSCN1 expression in bladder cancer
T Chiyomaru
1, H Enokida*,1, S Tatarano
1, K Kawahara
2, Y Uchida
1, K Nishiyama
1, L Fujimura
3, N Kikkawa
4,
N Seki
4 and M Nakagawa
1
1Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan;
2Kawahara Nephro-urology Clinic,
Kagoshima, Japan;
3Biomedical Research Center, Chiba University, Chiba, Japan;
4Department of Functional Genomics, Graduate School of Medicine,
Chiba University, Chiba, Japan
BACKGROUND: We have recently identified down-regulated microRNAs including miR-145 and miR-133a in bladder cancer (BC).
The aim of this study is to determine the genes targeted by miR-145, which is the most down-regulated microRNA in BC.
METHODS: We focused on fascin homologue 1 (FSCN1) from the gene expression profile in miR-145 transfectant. The luciferase assay
was used to confirm the actual binding sites of FSCN1 mRNA. Cell viability was evaluated by cell growth, wound-healing, and matrigel
invasion assays. BC specimens were subjected to immunohistochemistry of FSCN1 and in situ hybridisation of miR-145.
RESULTS: The miR-133a as well as miR-145 had the target sequence of FSCN1 mRNA by the database search, and both microRNAs
repressed the mRNA and protein expression of FSCN1. The luciferase assay revealed that miR-145 and miR-133a were directly
bound to FSCN1 mRNA. Cell viability was significantly inhibited in miR-145, miR-133a, and si-FSCN1 transfectants. In situ hybridisation
revealed that miR-145 expression was markedly repressed in the tumour lesion in which FSCN1 was strongly stained. The
immunohistochemical score of FSCN1 in invasive BC (n¼46) was significantly higher than in non-invasive BC (n¼20) (P¼0.0055).
CONCLUSION: Tumour suppressive miR-145 and miR-133a directly control oncogenic FSCN1 in BC.
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Bladder cancer (BC) is the fifth most common cancer in the United
States and the second most common cancer of the genitourinary
tract (Parkin et al, 2005; Jemal et al, 2008). In Japan, the age-
standardised mortality rate of BC has increased slightly since 1993
(Qiu et al, 2009). Currently, the standard diagnostic method
depends on the use of invasive urethro-cystoscopy. Bladder
tumour antigen and nuclear matrix protein-22 are available as
urine markers for BC diagnostic tools. However, they are not
widely used because of their low sensitivity and specificity for
distinguishing BC from non-malignant diseases (van Rhijn et al,
2005). In the treatment of BC, morphologically similar tumours
can behave differently, and it is currently not possible to identify
patients who will experience tumour recurrence or disease
progression (Kwak et al, 2004). Therefore, a new diagnostic
method and treatment based on BC biology are desired.
MicroRNAs are an abundant class of small non-coding RNAs of
about 22 nucleotides in length that function as negative regulators
of gene expression through antisense complimentarily to specific
messenger RNAs (Lagos-Quintana et al, 2001). Although their
biological functions remain largely unknown, recent studies
suggest that microRNAs contribute to the development of various
cancers (Schickel et al, 2008). The miR-145 and miR-133a/b have
been commonly identified as down-regulated in the microRNA
expression signatures of various human malignancies: head and
neck carcinoma (Wang et al, 2008; Wong et al, 2008a; Childs et al,
2009), pancreatic ductal adenocarcinoma (Szafranska et al, 2007),
lung cancer (Liu et al, 2009), breast cancer (Sempere et al, 2007;
Wang et al, 2009a), gastric cancer (Takagi et al, 2009), colorectal
cancer (Bandre ´s et al, 2006; Slaby et al, 2007; Schepeler et al, 2008;
Wang et al, 2009b), prostate cancer (Ozen et al, 2008; Tong
et al, 2009), and BC (Friedman et al, 2009; Lin et al, 2009a). In our
microRNA screening test of BC, we identified a subset of seven
differentially down-regulated microRNAs (miR-145, miR-133a,
miR-133b, miR-30a-3p, miR-195, miR-125b, and miR-199a*) among
the 156 microRNAs examined, and miR-145 was the most down-
regulated one of all (Ichimi et al, 2009). These studies strongly
suggest that low expression levels of miR-145 and miR-133a/b may
contribute to pathogenesis and progression of human malig-
nancies. Moreover, functional analyses of target genes, which
are repressed by these microRNAs, are crucial to elucidate the
mechanisms of cancer development. In this study, we performed an
oligo-microarray analysis of miR-145-transfected BC cell lines in
comparison with their parental cell lines for genome-wide screen-
ing of target genes silenced by miR-145 in BC, and we found that
fascin homologue 1 (FSCN1) was the most down-regulated one
among the genes.
FSCN1 is an actin-binding protein required for the formation of
actin-based cell-surface protrusions and cytoplasmic bundles of
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smicrofilaments (Hashimoto et al, 2005). FSCN1 activity is essential
to filopodial dynamics, and it has been proposed that fascin
imparts rigidity to the forming filopodia to efficiently push the
membrane forwards (Vignjevic et al, 2006). Cells with prominent
cytoplasmic protrusions and actively migrating cells express high
levels of FSCN1, whereas this protein is undetectable in most
normal epithelial cells (Pelosi et al, 2003). Over-expression of
FSCN1 in a variety of tumours such as lung (Pelosi et al, 2003),
prostate (Darnel et al, 2009), oesophageal (Zhang et al, 2006),
breast (Grothey et al, 2000), colon (Jawhari et al, 2003), pancreas
(Maitra et al, 2003), ovary (Lin et al, 2009b), and skin cancers
(Goncharuk et al, 2002) usually correlates with high-grade,
extensive invasion, distant metastasis, and poor prognosis.
However, little is known about the function of FSCN1 in BC, and
it is not known whether FCSN1 expression is regulated by specific
microRNAs.
We hypothesised that miR-145 and miR-133a/b directly regulate
FSCN1 and that FSCN1 has oncogenic activity in BC. We used
a luciferase reporter assay to determine whether FSCN1 actually
has sites targeted by miR-145 and miR-133a. To investigate the
functional roles of FSCN1 in BC, we performed a loss-of-function
study using BC cell lines. Furthermore, we evaluated FSCN1
protein expression in clinical BC specimens by immuno-
histochemistry.
MATERIALS AND METHODS
Clinical samples and cell culture
The tissue specimens were from 66 BC patients who had under-
gone cystectomy or transurethral resection of bladder tumours
at Kagoshima University Hospital between 2001 and 2005. The
patient’s background and clinico-pathological characteristics are
summarised in Table 1. These samples were staged according to
the American Joint Committee on Cancer-Union Internationale
Contre le Cancer tumour-node-metastasis classification and
histologically graded (Sobin and Wittekind, 2002). Normal bladder
epithelia (N1 and N2) were derived from patients with non-
cancerous disease and were used as the controls. Our study was
approved by the Bioethics Committee of Kagoshima University;
written prior informed consent and approval were given by the
patients. We used three human BC cell lines; BOY was established
in our laboratory from an Asian male patient aged 66 years, who
had a diagnosis of stage III BC with lung metastasis (Ichimi et al,
2009); T24 was obtained from American Type Culture Collection;
and KK47 was established in Kanazawa University and kindly
provided. These cell lines were maintained in a minimum essential
medium (MEM) supplemented with 10% foetal bovine serum in a
humidified atmosphere of 5% CO2 and 95% air at 371C.
Mature microRNA and siRNA transfection
As earlier described (Ichimi et al, 2009), the transfection of BC cell
lines was accomplished with RNAiMAX transfection reagent
(Invitrogen, Carlisbad, CA, USA), Opti-MEM (Invitrogen) with
10nM of mature microRNA molecules. For gain-of-function
experiments, we used Pre-miR and negative-control microRNA
(Applied Biosystems, Foster City, CA, USA), whereas FSCN1 siRNA
(LU-019576-00, J-019576-07, J-019576-08; Thermo Fisher Scientific,
Waltham, MA, USA) and negative-control siRNA (D-001810–10;
Thermo Fisher Scientific) were used for loss-of-function experi-
ments. Cells were seeded under the following conditions: 800000 in
a 10cm dish for protein extraction, 3000 per well in a 96-well plate
for XTT assay, 200000 per well in a 6-well plate for the wound-
healing assay, and 50000 per well in a 24-well plate for the mRNA
extraction, matrigel invasion assay, and luciferase assay.
Quantitative real-time RT–PCR
TaqMan probes and primers for FSCN1 (P/N: Hs00979631_g1;
Applied Biosystems) were assay-on-demand gene expression
products. All reactions were performed in duplicate and a
negative-control lacking cDNA was included. Regarding the PCR
conditions, we followed the manufacturer’s protocol. Stem-loop
RT–PCR (TaqMan MicroRNA Assays; Applied Biosystems) was
used to quantitate microRNAs according to the earlier published
conditions (Ichimi et al, 2009). For quantitative analysis of FSCN1
mRNA and the microRNAs, human 18s rRNA (P/N: Hs99999901_s1;
Applied Biosystems) and RNU48 (P/N: 001006; Applied Biosystems),
respectively, served as internal controls, and the delta–delta Ct
methods to calculate the fold change. We used premium total RNA
from normal human bladder (Clontech, Mountain View, CA, USA)
as a reference.
Gene expression analysis of BC cell lines
Total RNA was extracted by using TRIzol (Invitrogen) according to
the manufacturer’s protocol. The integrity of the RNA was checked
with an RNA 6000 Nano Assay kit and 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). Oligo-microarray Human
44K (Agilent Technologies) was used for expression profiling in
miR-145-transfected BC cell lines (T24 and KK47) in comparison
with miR-negative-control transfectant, as described earlier
(Sugimoto et al, 2009). Briefly, hybridisation and washing steps
were performed in accordance with the manufacturer’s instruc-
tions. The arrays were scanned using a Packard GSI Lumonics
ScanArray 4000 (Perkin Elmer, Boston, MA, USA). The data
obtained were analysed by means of DNASIS array software (Hitachi
Software Engineering), which converted the signal intensity for each
spot into text format. The Log2 ratios of the median subtracted
background intensity were analysed. Data from each microarray
study were normalised by the global normalisation method.
Western blots
After 3 days of transfection, protein lysate (50mg) was separated by
NuPAGE on 4–12% bis–tris gel (Invitrogen) and transferred into
a polyvinylidene fluoride membrane. Immunoblotting was carried
Table 1 Patient characteristics
Total number 66
Gender
Male 51
Female 15
Age
Median age (range) 72 (47–92) years
Stage
Superficial (pTa) 20
Invasive (XpT1) 46
Grade
G1 7
G2 41
G3 18
Operation
Cystectomy 17
TUR-BT 49
Recurrence
Yes 38
No 28
Abbreviation: TUR-BT¼transurethral resection of bladder tumour.
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sout with diluted (1:100) monoclonal FSCN1 antibody (ab49815,
Abcam, Cambridge, UK) and GAPDH antibody (MAB374; Chemi-
con, Temecula, CA, USA). The membrane was washed and then
incubated with goat anti-mouse IgG (HþL)-HRP conjugate (Bio-
Rad, Hercules, CA, USA). Specific complexes were visualised with
an echochemiluminescence detection system (GE Healthcare, Little
Chalfont, UK).
Cell growth, wound-healing, and matrigel invasion assays
Cell growth was determined by using an XTT assay (Roche Applied
Sciences, Tokyo, Japan) that was performed according to the
manufacturer’s instructions. Cell migration activity was evaluated
by wound-healing assay. Cells were plated in six-well dishes, and
the cell monolayer was scraped using a micropipette tip. The initial
gap length (0h) and the residual gap length 24h after wounding
were calculated from Photomicrographs. A cell invasion assay
was carried out using modified Boyden Chambers consisting of
transwell-precoated matrigel membrane filter inserts with 8mm
pores in 24-well tissue culture plates (BD Biosciences, Bedfold,
MA, USA). MEM containing 10% foetal bovine serum in the lower
chamber served as the chemoattractant. All experiments were
performed in triplicate.
Prediction of microRNA targets
To investigate the predicted target genes and their conserved sites
in which the seed region of each microRNA binds, we used the
TargetScan program (release 5.0, http://www.targetscan.org/). The
sequences of the predicted mature microRNAs were confirmed by
referring miRBase (release 13.0, http://microrna.sanger.ac.uk/).
Plasmid construction and dual-luciferase assay
MicroRNA target sequences were inserted between the XhoI–PmeI
restriction sites in the 30-UTR of the hRluc gene in psiCHECK-2
vector (C8021, Promega, Madison, WI, USA). BOY cells were
transfected with 5ng of vector, 10nM of microRNAs, and 1mlo f
Lipofectamine 2000 (Invitrogen) in a 100ml Opti-MEM. The activities
of firefly and Renilla luciferases in cell lysates were determined with
a dual-luciferase assay system (Promega). Normalised data were
calculated as the quotient of Renilla/firefly-luciferase activities.
Immunohistochemistry
The primary mouse monoclonal antibodies against FSCN1
(Abcam) were diluted by 1:200. The slides were treated with
Biotinylated Anti-Mouse IgG (HþL) made in horse (Vector
laboratories, Burlingame, CA, USA). Diaminobenzidine-hydrogen
peroxide (Sigma-Aldrich, St Louis, MO, USA) was the chromogen,
and the counterstaining was carried out with 0.5% haematoxylin.
The positivity of endothelia and myofiblasts served as an inner
positive control. The intensity of the staining was scored as
negative (0), weak (1), moderate (2), or strong (3) (Ropponen et al,
1999). All staining scores are averages of duplicate experiments,
and all samples were independently scored by two of us (TC and
HE) who were blinded to the patient status.
In situ hybridisation of microRNA
In situ hybridisation was carried out according to the manufac-
turer’s protocol for formalin-fixed, paraffin-embedded (FFPE)
tissue (Kloosterman et al, 2006) on human BC specimens. DIG-
labelled LNA oligo-nucleotides were purchased from EXIQON
(Woburm, MA, USA) and used for overnight hybridisation at 521C.
The staining was carried out as described earlier. After depar-
affinisation, the specimens were subjected to proteinase K (20Ag
per ml) digestion for 20min. The post-fixed tissues were subse-
quently incubated overnight with the locked nucleic acid-modified
probes. For the immunodetection, tissues were incubated overnight
at 41C in anti-DIG-AP FAB fragment (Roche Applied Sciences;
1/2000). The final visualisation was carried out with NBT/BCIP
(Pierce, Rockford, IL, USA).
Statistical analysis
The relationship between two variables and the numerical values
obtained by real-time RT–PCR was analysed using the Mann–
Whitney U-test. The relationship between three variables and the
numerical values was analysed using the Bonferroni-adjusted Mann–
Whitney U-test. The analysis software was Expert StatView (version
4, SAS Institute Inc., Cary, NC, USA); for the comparison test among
the three variables, a non-adjusted statistical level of significance of
Po0.05 corresponds to a Bonferroni-adjusted level of Po0.0167.
RESULTS
Gene expression profile identifying down-regulated genes
in miR-145 transfectant
For genome-wide screening of target genes silenced by miR-145
in BC, we performed an oligo-microarray analysis of miR-145-
transfected BC cell lines (T24 and KK47) in comparison with miR-
negative-control transfectant. A total of 200 genes were generally
down-regulated by 40.5-fold in miR-145 transfectants compared
with the control. We focused on FSCN1 because it was listed as the
top candidate in the expression profile (Table 2).
FSCN1 as a target of post-transcriptional repression by
miR-145 and miR-133a
Among the T24 cell lines transfected with the six down-regulated
microRNAs in our earlier study (Ichimi et al, 2009), the expression
levels of FSCN1 mRNA and its protein were markedly decreased
not only in miR-145, but also in miR-133a transfectants (Figure 1A
and B). We performed a luciferase assay to determine whether
FSCN1 mRNA actually has the target sites of these two microRNAs,
as indicated by the TargetScan algorithm. We initially used the
vector encoding full-length 30-UTR of FSCN1 mRNA (position
51–1180), and the luminescence intensity was significantly
decreased in miR-145 and miR-133a transfectants (Figure 2A).
Furthermore, to determine the specific sites targeted by the two
microRNAs, we constructed vectors covering four conserved sites
for miR-145 and one site for miR-133a (Figure 2B). The lumi-
nescence intensity was significantly decreased at the two sites
targeted by miR-145 (positions 377–383 and 1140–1146) and
one site targeted by miR-133a (position 745–751) (Figure 2B). In
addition, we constructed three mutated vectors in which the specific
sites targeted by the microRNAs were deleted, and the luminescence
intensity was not decreased at all by miR-145 and miR-133a
(Figure 2C). We did not examine miR-133b because it was consi-
dered to function similarly to miR-133a; these microRNAs have very
similar sequences (miR-133a: UUGGUCCCCUUCAACCAGCUGU,
miR-133b: UUGGUCCCCUUCAACCAGCUA) and have a common
sequence for binding to FSCN1 mRNA (UUGGUC) (Figure 2B).
Effect of miR-145 and miR-133a transfection on cell
growth, invasion, and migration activity in BC cell lines
The expression levels of miR-145 and miR-133a were extremely
low in the BC cell lines compared with normal bladder epithelia
(N1 and N2) (Figure 3A), suggesting that endogenous miR-145 or
miR-133a in these cell lines does not affect cell viabilities. There-
fore, we performed gain-of-function studies using the microRNA
transfectants to investigate the functional role of miR-145 and
miR-133a. The XTT cell-growth assay showed significant cell-
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sgrowth inhibitions in miR-145 and miR133a transfectant compared
with the controls from BOY and T24 cell lines (BOY, 86.6±1.6,
65.7±0.3, 100±0.6, respectively, Po0.0001; and T24, 87.4±0.6,
69.5±1.5, 100±0.9, respectively, Po0.0005; Figure 3B). The
wound-healing assay showed significant cell migration inhibitions
in miR-145 and miR133a transfectant (BOY, 59.0±3.5, 58.1±3.4,
100.0±2.4, respectively, Po0.0001; and T24, 74.5±2.5, 72.3±4.0,
100.0±2.7, respectively, Po0.0001; Figure 3C). The matrigel
invasion assay also showed significant cell invasion inhibitions
in the transfectants compared with the control from the BOY cell
lines (35.625±4.606, 24.000±4.516, 182.000±18.678, Po0.0001;
Figure 3D). However, no significant difference was observed in the
miR-145 and miR-133a transfectants from T24 cell lines
(173.875±16.607, 140.125±6.799, 167.000±27.367; Figure 3D).
We did not subject KK47 cell line to these experiments because it
showed a focal growth and it was not suitable for the experiments.
Effect of FSCN1 knockdown on cell growth, invasion, and
migration activity in BC cell lines
The expression levels of FSCN1 mRNA were more than three-fold
higher in BC cell lines than in the control (normal human bladder
RNA). To examine the functional role of FSCN1, we performed loss
of function studies using si-FSCN1-transfected T24 cell lines,
which showed higher FSCN1 mRNA expression levels compared
with BOY (Figure 4A, upper). We did not subject KK47 cell line to
these experiments because it showed a focal growth and it was not
suitable for the experiments. FSCN1 protein expression was
repressed by si-FSCN1 transfection (Figure 4A, lower). The XTT
assay revealed significant cell-growth inhibition in the three
si-FSCN1 transfectants in comparison with that in the si-control
transfectant (% of cell viability; 69.9±1.3, 88.7±2.0, 58.0±1.4,
and 100.0±1.3, respectively, Po0.0001; Figure 4B). The wound-
healing assay also showed significant cell migration inhibitions
in the si-FSCN1 transfectant compared with the counterparts (%
of wound closure; 70.9±2.5, 49.4±2.5, 34.2±2.6, and 100.0±2.6,
respectively, Po0.0001; Figure 4C). The matrigel invasion assay
showed that the number of invading cell was significantly
decreased in the si-FSCN1 transfectant compared with the
counterparts (% of cell invasion; 39.0±4.6, 35.1±2.9, 18.3±2.5,
and 100.0±3.9, respectively, Po0.0001; Figure 4D).
Immunohistochemistry of FSCN1 and in situ hybridisation
of miR-145 in clinical BC samples
To visualise FSCN1 expression and the related microRNA
expression in a tumour lesion and surrounding normal tissues,
we performed immunohistochemistry of FSCN1 and in situ
FSCN1 55 kDa
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Figure 1 Regulation of FSCN1 expression in the down-regulated microRNA transfectants (T24). (A) FSCN1 mRNA expression after 24h transfection
with 10nM of microRNAs (miR-145, miR-30a-3p, miR-133a, miR-195, miR-125b, and miR-199a*). FSCN1 mRNA expression was repressed in miR-145 and
miR-133a transfectants. (B) FSCN1 protein expression after 72h transfection of microRNAs. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as a loading control. The protein expression level of FSCN1 was also repressed in the transfectants.
Table 2 Top 20 genes that were down-regulated by 40.5-fold in miR-145 transfectants in comparison with the control
Entrez gene ID Gene symbol Gene name Log2 ratio
6624 FSCN1 Fascin homologue 1, actin-bundling protein (Strongylocentrotus purpuratus)  3.95
10447 FAM3C Family with sequence similarity 3, member C  3.26
203547 LOC203547 Hypothetical protein LOC203547  3.17
2519 FUCA2 Fucosidase, a-L-2, plasma  2.88
51280 GOLM1 Golgi membrane protein 1  2.85
56674 TMEM9B TMEM9 domain family, member B  2.85
5094 PCBP2 Poly(rC)-binding protein 2  2.81
84841 MGC15634 Hypothetical protein MGC15634  2.80
2764 GMFB Glia maturation factor, b  2.63
91452 ACBD5 Acyl-coenzyme A-binding domain containing 5  2.61
7048 TGFBR2 Transforming growth factor, b receptor II (70/80kDa)  2.57
8508 NIPSNAP1 Nipsnap homologue 1 (Caenorhabditis elegans)  2.55
23075 SWAP70 SWAP-70 protein  2.54
92675 DTD1 D-tyrosyl-tRNA deacylase 1 homologue (Saccharomyces cerevisiae)  2.53
27250 PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor)  2.52
57552 AADACL1 Arylacetamide deacetylase-like 1  2.49
4697 NDUFA4 NADH dehydrogenase (ubiquinone) 1 a subcomplex, 4, 9kDa  2.46
5530 PPP3CA Protein phosphatase 3 (formerly 2B), catalytic subunit, a isoform  2.39
51199 NIN Ninein (GSK3B-interacting protein)  2.26
89894 TMEM116 transmembrane protein 116  2.03
Abbreviation: NADH¼nicotinamide adenine dinucleotide.
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Position 116–122 of 3′UTR Position 377–383 of 3′UTR Position 729–735 of 3′UTR Position 1140–1146 of 3′UTR
0.1K
5′ . . . CCCCCUUGCCUUUCA - AACUGGAA . . .
3′        UCCCUAAGGACCCUUUUGACCUG
5′. . . CUGGGCGUGUAGUGUAACUGGAA . . . 5′. . . UUUCACCCUAGCCUGACUGGAAG . . .
5′. . . CUGGAAGCAGAAAAUGACCAAAU . . .
. . . CUGGGCGUGUAGUGU - - - - - - - A . . .
UCCCUAAGGACCCUUUUGACCUG
Position 377–383 of 3′UTR Position 745–751 of 3′UTR Position 1140–1146 of 3′UTR
GUCGACCAACUUCCCCUGGUUU UCCCUAAGGACCCUUUUGACCUG
. . . CUGGAAGCAGAAAAU- - - - - - A . . . . . AUGAUAGUAGCUUCA - - - - - - - A . . .
3′     GUCGACCAACUUCCCCUGGUUU
Position 745–751 of 3′UTR
5′. ..AUGAUAGUAGCUUCAAACUGGAA . . .
3′      UCCCUAAGGACCCUUUUGACCUG 3′    UCCCUAAGGACCCUUUUGACCUG 3′    UCCCUAAGGACCCUUUUGACCUG
0.2K 0.3K 0.4K 0.5K 0.6K 0.7K 0.8K 0.9K 1.0K 1.1K
Control miR-145 miR-133a
0.2K
Human FSCN1 (NM_003088) 3′UTR length: 1180
0.3K 0.4K 0.5K 0.6K 0.7K 0.8K 0.9K 1.0K 1.1K
Figure 2 miR-145- and miR-133a-binding sites in FSCN1 30-UTR. (A) A luciferase assay using the vector encoding full length of FSCN1 30-UTR (position
51–1180). BOY cells were transfected with 5ng vector and 10nM microRNAs. The Renilla luciferase values were normalised by firefly-luciferase values.
(B) Luciferase assays using the vectors encoding putative conserved target sites of FSCN1 30-UTR identified with the TargetScan database: four conserved
sites for miR-145 and one site for miR-133a.( C) Luciferase assays using the mutated vectors in which the specific sites targeted by the microRNAs
were deleted.
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showed a high-grade tumour lesion surrounded by smooth muscle
layers (Figure 5A). Immunohistochemistry revealed that FSCN1
was markedly expressed in the tumour lesion, whereas no
expression was observed in adjacent tissues including the smooth
muscle layers (Figure 5B). In contrast, miR-145 was faintly
expressed in the tumour lesion with the strong expression in the
smooth muscle layers (Figure 5C). The scramble-control probe
showed no significant staining in either the tumour or the smooth
muscle layers (Figure 5D). Figure 5E shows immunostaining of
FSCN1 in a non-invasive BC (pTa) and an invasive BC with
involvement of the muscularis (pT2). There was faint staining in
the non-invasive BC, whereas there was strong staining of cytosol
and nuclei in the invasive BC. The staining score of the invasive BC
(XpT1) was significantly higher than that of the non-invasive BC
(pTa) (1.62±0.05 vs 1.33±0.07, P¼0.0055). We found no
correlation between FSCN1 expression and clinico-pathological
parameters except for tumour stage.
DISCUSSION
Earlier studies showed that miR-145 and miR-133a are commonly
down-regulated in several human cancers and that their transfec-
tion reduces cell proliferation of each cancer cell line (Bandre ´s
et al, 2006; Sempere et al, 2007; Slaby et al, 2007; Szafranska et al,
2007; Ozen et al, 2008; Schepeler et al, 2008; Wang et al, 2008,
2009a,b; Wong et al, 2008a; Childs et al, 2009; Friedman et al,
2009; Liu et al, 2009; Takagi et al, 2009; Tong et al, 2009; Lin et al,
2009a). Consistent with earlier studies, we found significant
cell-growth inhibitions in BC cell lines transfected with miR-145
and miR-133a precursors. These results suggest that these
microRNAs may have tumour suppressive functions through
regulating oncogenic genes in human malignancies. Regarding BC,
miR-145 was listed in two of the three earlier studies investigating
microRNA signatures in BC compared with normal control
(Friedman et al, 2009; Lin et al, 2009a,b). Moreover, this study
is the first to show that miR-133a is a down-regulated microRNA
in BC. An earlier study showed that miR-133a is abundantly
expressed in muscle cells, and it may have a part in regulating
proliferation and differentiation (McCarthy and Esser, 2007).
Regarding the target genes, there are only three earlier studies
showing that miR-145 directly binds to c-Myc (Sachdeva et al,
2009) and insulin receptor substrate-1 (Shi et al, 2007), which are
associated with cell proliferation and that miR-133a/b directly
binds to pyruvate kinase type M2 expression, which is a potent
oncogene in solid cancers (Wong et al, 2008b). Down-regulation of
these microRNAs may have a critical function in BC development.
Our cell invasion assay showed that there were significant
decreases of invading cell number in the miR-145 and miR133a
transfectants from BOY, but not from T24 BC cell lines. These
results suggest that another pathway might be more crucial than
FSCN1 for invasiveness in some BCs. To find the target genes,
web-based software was used in the earlier studies. However, the
many candidate microRNAs identified by the web-based software
often make it more difficult for researchers to find the crucial
target genes. In this study, we used an oligo-microarray to
screen the candidates from gene expression profiles in miR-145
transfectant and found a new target gene, FSCN1, which was
subsequently validated by the luciferase reporter assay. Thus,
gene expression profiles from specific microRNA transfectant may
be a good strategy for finding candidate genes targeted by
microRNA.
FSCN1 functions in two major forms of actin-based structures:
cortical cell protrusions that mediate interactions between cells
and the extra-cellular matrix (ECM), cell-to-cell interactions, and
cell migration; and cytoplasmic microfilamentous bundles that
contribute to cell architecture and intracellular movements
(Kureishy et al, 2002). The fascin–actin interaction is affected by
extra-cellular cues, and certain ECM components induce bundling
of actin by FSCN1 (Hashimoto et al, 2005). It is plausible that the
activation of fascin through ECM substrates contributes to tumour
growth, migration, and invasion. In BC, FSCN1 over-expression
has been noted in three different immunohistochemistry studies
(Tong et al, 2005; Karasavvidou et al, 2008; Soukup et al, 2008).
Our immnohistochemical study consistently showed that the
expression levels of FSCN1 were correlated with advanced tumour
stage. In addition, tumour viability was markedly decreased in
FSCN1-knockdown BC cell lines. These results strongly suggest
that this molecule may function as an oncogene. It may be deeply
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biomarker for clinical BC.
Regarding FSCN1 regulation, several studies have reported that
the actin-binding activity of fascin is inhibited by phosphorylation
of residue Ser-39 by protein kinase Ca (Adams et al, 1999);
b-catenin/T cell factor signalling transactivates the FSCN1 pro-
moter in human colon carcinoma cell lines (Vignjevic et al, 2007);
and FSCN1 down-regulation is associated with a decrease in
b-catenin and c-erbB-2 expression (Xie et al, 2005). However, to
our knowledge, there has been no earlier study reporting the
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We earlier reported that miR-145 and miR-133a expressions are
significantly down-regulated in BC tissue compared with normal
bladder epithelium (Ichimi et al, 2009). In this study, we showed
that miR-145 and miR-133a directly target FSCN1, resulting in
decreased FSCN1 mRNA and its protein levels both in vitro and in
clinical specimens. The question of how FSCN1 becomes over-
expressed is still open, but one possible mechanism is through
regulation by microRNAs. Loss of miR-145 and miR-133a, both of
which are endogenous FSCN1 inhibitors, may promote aberrant
expression of FSCN1 contributing to pathogenesis and progression
of BC.
In summary, through our microRNA profiling in BC, we have
found that FSCN1 might have an oncogenic function in BC and
miR-145 and miR-133a might function as tumour suppressors
through direct repression of FSCN1 in BC. As viral vector-
mediated microRNA transduction might be applicable in vivo
(Yang et al, 2006), our findings raise the possibility that miR-145
and miR-133a may have potential therapeutic value in BC patients.
In addition, FSCN1 may be a potential target for gene therapy of
BC. As down-regulation of miR-145 and miR-133a and over-
expression of FSCN1 were commonly identified in various human
malignancies, our findings may be crucial events in the develop-
ment throughout human malignancies.
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